JOTROL PK, Safety, and Food Effect Assessment

NCT04668274 | Completed Phase 1 Results DMC FDA Drug

• 2 other identifiers: Protocol 202016R44AG067907-01A1
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Type of Study: Single Ascending Doses (SAD) Study Objectives: To characterize the pharmacokinetic (PK) profile of JOTROL (resveratrol) following oral administration of SAD ranging from 200 mg up to a dose currently estimated at 1,000 mg, in healthy subjects. To evaluate the safety and tolerability of JOTROL To evaluate the effect of food on the PK profile of JOTROL. Study Design: Phase I, randomized, open-label, sequential SAD study with a food effect evaluation. Blood plasma and urine samples will be assessed for resveratrol and key metabolite content. Type of Control: No control Test Product: JOTROL (resveratrol) 100 mg resveratrol in 1000 mg softgel capsule for oral administration Dosage Regimen: Planned dose levels of resveratrol: 200 mg, 500 mg, and 1,000 mg. Following completion of each dose level, PK, safety, and tolerability data will be evaluated; dose levels may be adjusted. Route of Administration: Oral gelcaps with water Number of Subjects: 24 subjects will be included in Part 1; only 16 subjects, who completed Part 1, will be included in Part 2. Subjects: Healthy, non-smoker, adult males or females, ≥ 18 and ≤ 75 years of age Study Duration: Participation of each subject in this study should last approximately 1 to 1.5 months (for subjects participating in study Part 1 only) and 1.5 to 2 months (for subjects participating in both study parts).

Conditions

Pharmacokinetics; Safety; Food-drug Interaction

Outcome Measures

Primary Outcomes (4)

• Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  An adverse event (AE) was defined as any untoward medical occurrence (including clinically significant \[CS\] vital signs measurements or laboratory results) or worsening of a pre-existing condition in a participant administered a pharmaceutical product during the course of the study, whether related or not to the study medication. TEAEs were defined as AE that occurred on or after the date and time of study drug administration or those that first occurred pre-dose but worsened by increase in occurrence or severity after study drug administration. TEAEs includes both serious and non-serious TEAEs.

  From first dose of study drug administration up to 131 days

• Area Under the Plasma Concentration-time Curve From Time 0 to Time of Infinity (AUC0-inf) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)

  AUC(0-infinity) of resveratrol, resveratrol-3-glucuronide, resveratrol-4'-glucuronide, and resveratrol-3-sulfate in plasma were reported. AUC(0-infinity) of resveratrol, resveratrol-3-glucuronide, resveratrol-4'-glucuronide, and resveratrol-3-sulfate in plasma were reported and calculated as AUC0-t + Ct/Kel, where Ct is the last observed measurable concentration, AUC0-t is Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration and Kel is Elimination rate constant.

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)

  AUC0-t was Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration. AUC(0-t) was calculated according to the mixed log-linear trapezoidal rule.

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Maximum Observed Plasma Concentration (Cmax) for Resveratrol and Its Metabolites (Resveratrol-3-glucuronide, Resveratrol-4'-Glucuronide, and Resveratrol-3-sulfate)

  Cmax was the maximum observed plasma concentration obtained directly from the concentration versus time curve.

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

Secondary Outcomes (8)

• Residual Area for Resveratrol

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Time to Maximum Observed Plasma Concentration (Tmax) for Resveratrol

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Elimination Half-Life (T1/2 el) for Resveratrol

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Elimination Rate Constant (Kel) for Resveratrol

  Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1

• Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t) for Resveratrol

  Pre-dose and 4, 8, 12, 24, and 32 hours post-dose on Day 1

Study Arms (4)

Part 1: JOTROL (Resveratrol) 200 mg (Treatment A)

EXPERIMENTAL

Participants received JOTROL (resveratrol) 200 (2\*100) milligram (mg) (Treatment A), gelatin capsule (gelcap), orally, once on Day 1 in fasted conditions in Study Period 1.

Drug: 200 mg resveratrol as JOTROL

Part 1: JOTROL (Resveratrol) 500 mg (Treatment B)

EXPERIMENTAL

Participants who completed Study Period 1 received JOTROL (resveratrol) 500 (5\*100) mg (Treatment B), gelcap, orally, once on Day 1 in fasted conditions in Study Period 2. A 14 days washout period was maintained in study period 1 and 2.

Drug: 500 mg resveratrol as JOTROL

Part 1: JOTROL (Resveratrol) 700 mg (Treatment C)

EXPERIMENTAL

Participants who completed Study Period 2 received JOTROL (resveratrol) 700 (7\*100) mg (Treatment C), gelcap, orally, once on Day 1 in fasted conditions in Study Period 3. A 14 days washout period was maintained in study period 2 and 3.

Drug: 700 mg resveratrol as JOTROL

Part 2: JOTROL (Resveratrol) 500 mg (Treatment D)

EXPERIMENTAL

Participants who completed Study Period 3 (Part 1) received JOTROL (resveratrol) 500 (5\*100) mg (Treatment D), gelcap, orally, once on Day 1 in fed conditions in Study Period 4. A 14 days washout period was maintained in study period 3 and 4.

Drug: 500 mg resveratrol as JOTROL administered to assess influence of food

Interventions

200 mg resveratrol as JOTROL DRUG

Low (first) dose of single ascending dose study

Part 1: JOTROL (Resveratrol) 200 mg (Treatment A)

500 mg resveratrol as JOTROL DRUG

Second (intermediate) dose of single ascending dose study

Part 1: JOTROL (Resveratrol) 500 mg (Treatment B)

700 mg resveratrol as JOTROL DRUG

Third (highest) dose of single ascending dose study

Part 1: JOTROL (Resveratrol) 700 mg (Treatment C)

500 mg resveratrol as JOTROL administered to assess influence of food DRUG

500 mg resveratrol as JOTROL administered to assess influence of food

Part 2: JOTROL (Resveratrol) 500 mg (Treatment D)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Normal healthy male or female volunteers, non-smokers (no use of tobacco products within 3 months prior to screening), ≥ 18 and ≤ 75 years of age, with BMI \> 18.5 and \< 30.0 kg/m 2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females
• Healthy as defined by:
• the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease as determined by the Investigator.
• Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration:
• intra-uterine contraceptive device without hormone release system placed at least 4 weeks prior to study drug administration;
• male condom with intravaginally applied spermicide starting at least 21 days prior to study drug administration;
• sterile male partner (vasectomized since at least 6 months).
• Capable of consent

You may not qualify if:

• Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
• Positive urine drug screen or urine cotinine test at screening.
• History of allergic reactions to resveratrol, polyphenols, other related drugs, .
• or to any excipient in the formulation
• Positive pregnancy test at screening.
• Breast-feeding subject.
• Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
• History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week \[1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]).
• History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
• Use of resveratrol for a medical condition or in the context of another clinical trial within a period of 30 days prior to the first dosing.
• Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
• Use of medications for the timeframes specified below, with the exception of medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):
• prescription medication within 14 days prior to the first dosing;
• over-the-counter products and natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 14 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);
• use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first study drug administration, including St John's wort;

Sponsors & Collaborators

• Jupiter Orphan Therapeutics Inc.: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

inVentiv Health Clinical Research Services LLC, a Syneos Health company (" Syneos Health ")

Miami, Florida, 33136, United States

Location

Related Publications (1)

• Kemper C, Benham D, Brothers S, Wahlestedt C, Volmar CH, Bennett D, Hayward M. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM). AAPS Open. 2022;8(1):11. doi: 10.1186/s41120-022-00058-1. Epub 2022 Jun 30.

  PMID: 35789594 DERIVED

MeSH Terms

Interventions

Resveratrol

Intervention Hierarchy (Ancestors)

Stilbestrols; Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polyphenols; Phenols

Results Point of Contact

• Title: David Wyatt
• Organization: Marshall A. Hayward, Ph.D., Jupiter Orphan Therapeutics Inc.

david.wyatt@syneoshealth.com

305-547-5857

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 2, 2020
• First Posted: December 16, 2020
• Study Start: January 21, 2021
• Primary Completion: February 28, 2021
• Study Completion: May 31, 2021
• Last Updated: August 12, 2022
• Results First Posted: August 12, 2022

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)